Literature DB >> 22409250

Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura.

John Chapin, Babette Weksler, Cynthia Magro, Jeffrey Laurence.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22409250     DOI： 10.1111/j.1365-2141.2012.09084.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  35 in total

1.  Clinical-Pathological Conference Series from the Medical University of Graz Case No 155: 26-year-old woman in third trimester of pregnancy with epigastric pain and thrombocytopenia.

Authors:  Elisabeth Fabian; Florian Eisner; Ingrid Pabinger; Christian Viertler; Sigrid Regauer; Andreas Lueger; Peter Neumeister; Eva-Christine Weiss; Wolfgang Schöll; Uwe Lang; Florian Prüller; Guenter J Krejs
Journal:  Wien Klin Wochenschr       Date:  2015-08-07       Impact factor: 1.704

2.  Acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome successfully treated with eculizumab.

Authors:  Appalanaidu Sasapu; Michele Cottler-Fox; Pooja Motwani
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

Review 3.  Complement: an overview for the clinician.

Authors:  Juan Carlos Varela; Stephen Tomlinson
Journal:  Hematol Oncol Clin North Am       Date:  2015-04-04       Impact factor: 3.722

Review 4.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 5.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

Review 6.  Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Authors:  Julien Zuber; Fadi Fakhouri; Lubka T Roumenina; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

Review 7.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

8.  Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.

Authors:  Cynthia M Magro; Shabnam Momtahen; Joseph Justin Mulvey; Aminah H Yassin; Robert B Kaplan; Jeffrey C Laurence
Journal:  Am J Dermatopathol       Date:  2015-05       Impact factor: 1.533

9.  Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

10.  Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy.

Authors:  Ramesh Tati; Ann-Charlotte Kristoffersson; Anne-Lie Ståhl; Johan Rebetz; Li Wang; Christoph Licht; David Motto; Diana Karpman
Journal:  J Immunol       Date:  2013-07-22       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.